Ownership Summary
According to SEC filings for the period ending December 2025, Chemomab Therapeutics Ltd. (NASDAQ:CMMB) is held by 9 institutional firms.
- The collective stake of institutional investors in Chemomab Therapeutics moved to 2.7% in December 2025, a shift down from the 10.2% reported for September 2025.
- On a quarter-over-quarter basis, institutional holdings shifted by -20.19%, with a year-over-year a decrease of 47.06% in the count of filers.
- During the quarter, 6 institutions bought more Chemomab Therapeutics shares, 2 sold shares, and 1 of the 9 total investors held their position steady.
- The total number of shares held by institutions in Chemomab Therapeutics decreased to 101.86K as of December 2025, a net change of down by 25.76K shares quarter on quarter, and down 4.06Mn shares year over year.
- KESTRA PRIVATE WEALTH SERVICES, LLC's holding of 51.71K shares as of December 31, 2025 makes it the primary institutional investor in Chemomab Therapeutics, owning 1.35% of the stock.
- Among the most significant buyers of Chemomab Therapeutics during December 2025 were KESTRA PRIVATE WEALTH SERVICES, LLC (51.71K), RHUMBLINE ADVISERS (8.35K), BNP PARIBAS FINANCIAL MARKETS (2.38K), UBS Group AG (2.15K), GAMMA Investing LLC (1.85K).
- Leading sellers of Chemomab Therapeutics stock in December 2025 included MORGAN STANLEY (86.29K), JANE STREET GROUP, LLC (5.91K).
- The top 9 institutional holders of Chemomab Therapeutics for the quarter ending December 2025 included KESTRA PRIVATE WEALTH SERVICES, LLC (51.71K), RHUMBLINE ADVISERS (17.86K), JANE STREET GROUP, LLC (15.60K), BNP PARIBAS FINANCIAL MARKETS (8.12K), MORGAN STANLEY (3.77K), GAMMA Investing LLC (2.51K), UBS Group AG (2.25K), SBI Securities Co., Ltd. (26), NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO (2).